Introduction
Cellular senescence is a state of permanent proliferation arrest that cannot be overcome by addition of mitogenic stimuli. In addition to this loss of proliferation potential, adherent senescent cells show a characteristic set of morphological changes, which includes flattening, enlargement, and an increase in cytoplasmic granularity and vacuolization. Senescence was originally described as a phenomenon that primary (non-transformed) cells underwent after serial passage in cell culture. This is now known to be due to the gradual loss of telomeric repeats from the ends of chromosomes during cell divisions. This ultimately leads to the activation of a DNAdamage response that triggers a sustained state of proliferation arrest (di Fagagna et al., 2003) . This senescence phenomenon is now referred to more specifically as replicative senescence to distinguish it from a related phenomenon known as premature senescence, which has overlapping features with replicative senescence (Schmitt, 2007) . Premature senescence can occur in response to either oncogene activation or stress. Thus, for example, introduction of mutant, oncogenic KRAS into many primary cell types induces an irreversible proliferation arrest, along with similar morphological and biochemical changes to those seen in cells undergoing replicative senescence. This phenomenon, referred to as oncogene-induced senescence, appears to be an important endogenous cancer control mechanism in the human body. The best example of this are the cells found in the naevi (moles) present on the skin of many humans. These often have oncogenic mutations but have undergone senescence and therefore fail to develop into malignant cancers (Pollock et al., 2003; Michaloglou et al., 2005) .
Cancer cells clearly develop the ability to evade both replicative and premature senescence. However there is substantial evidence that this can be overcome under specific circumstances and that senescence induction is a legitimate additional strategy to block cancer cell proliferation (Schmitt, 2007) . This was first shown with DNA-damaging chemotherapy agents, which can induce premature senescence in many cancer cell types (Gewirtz et al., 2008 ). It appears that oncogenic mutations increase the threshold for a DNA-damagetriggered senescence response in these cells, but do not completely abrogate the senescence response. A second strategy to induce senescence in cancer cells may be simply to turn off the suppression of oncogene-induced senescence (Ventura et al., 2007; Wu et al., 2007) . An exciting aspect of this approach is that it provides a mechanism for selectivity for cancer cells over normal cells, as oncogenic signals unique to the cancer cells can drive them into senescence.
The phosphoinositide-3-kinase (PI-3-kinase) pathway is aberrantly activated in the majority of cancers, either by activation of receptor tyrosine kinases, loss of the tumor suppressor PTEN or mutational activation of PI-3-kinase itself. Mutational activation of PI-3-kinase most frequently occurs as a result of point mutations in the PIK3CA gene, which are found in 25-30% of breast cancers and at a lower frequency in other cancer types (Karakas et al., 2006) . Amplification of the PIK3CB gene has also been reported, although this appears to be a relatively rare event (Crowder et al., 2009 ). All of these events lead to the generation of the second messenger phosphoinositide-3,4,5-trisphosphate on the inner leaflet of the plasma membrane. This leads to the activation of multiple downstream kinases through phosphoinositidedependent kinase-1 (PDK1). While PKB/Akt is the most widely studied of these kinases, multiple other kinases also require PDK1 phosphorylation for their activation, including the atypical PKCs (Peifer and Alessi, 2008) .
There are two members of the atypical PKC family, PKCz and PKCi (PKCl in mice). Both of the atypical PKCs are distinguished from the other members of the PKC family by their lack of dependence on diacylglycerol for activation. PKCi is activated by PDK1 phosphorylation either on its own or in association with a complex of an activated member of the Cdc42 family of GTPases and Par6 (Kanzaki et al., 2004) . Of the two enzymes, PKCi is the most ubiquitously expressed and there is now considerable evidence linking PKCi to the transformed phenotype (Fields and Regala, 2007) . It is overexpressed in multiple cancer types, and studies of both mouse models and human cancer cell lines show an important role in the growth, invasion and resistance to apoptosis of a variety of cancer cell types. In glioblastoma, PKCi represses apoptosis and promotes invasion (Baldwin et al., 2006 (Baldwin et al., , 2008 . PKCi also has a key role in the pathogenesis of lung, ovarian and pancreatic cancer (Eder et al., 2005; Regala et al., 2005; Zhang et al., 2006) . Several previous studies have provided evidence for a role for the PI-3-kinase pathway in senescence. In cultured mouse embryonic fibroblasts, the PI-3-kinase inhibitors LY294002 and wortmannin induce senescence (Collado et al., 2000) . In mouse models of melanoma, whereas BRAF activation in melanocytes mimics the generation of senescent cells described in human naevi, BRAF activation in mice deleted for PTEN leads to the formation of malignant tumors (Dankort et al., 2009) . In contrast to these studies that indicate a role for the PI-3-kinase pathway in suppressing oncogene-induced senescence, other studies have indicated a role for the PI-3-kinase pathway in driving oncogene-induced senescence. Chen et al. (2005) have shown that, in mouse models of prostate cancer, loss of PTEN drives cells into senescence. Yuan et al. (2011) have shown data indicating that high levels of PI-3-kinase activity can drive breast epithelial cells into senescence. These differences may be a reflection of the striking tissuespecific effects of relatively small changes in signaling through the PI-3-kinase pathway (Carracedo et al., 2011) . Here we show that PKCi is overexpressed in breast cancer cells and that this overexpression is driven, in part, by mutational activation of PIK3CA. Overexpressed PKCi functions to suppress oncogene-induced senescence in breast cancer cells, and also in glioblastoma cells where PKCi is activated by loss of PTEN.
Results

PKCi expression in breast cancer
PKCi expression in breast cancer was assessed by immunohistochemistry. The monoclonal antibody used for this recognizes a single band on western blots of breast cancer cell lines and, unlike some polyclonal antibodies, is specific for PKCi and does not bind to PKCz. Three different commercial tissue microarrays were analyzed for PKCi expression. These were as follows: a tissue microarray with cores from 36 breast cancer cases and 12 cases of non-malignant breast cancer tissue; a tissue microarray with cores from 50 breast cancer cases and matched lymph node metastases; and a tissue microarray with 5 cases of normal tissue, 12 hyperplasia cases, 12 carcinoma in situ and 12 invasive carcinomas. Stained slides were scored by two pathologists using scanned digital images of slides and the TMA Software from Aperio. Representative examples of staining are shown in Figure 1 . In normal breast tissue there were very low levels of PKCi cytoplasmic staining in both luminal and myoepithelial cells of the duct, as well as the surrounding stromal cells. The distribution of scores for hyperplasia, ductal carcinoma in situ, invasive ductal carcinoma and lymph node metastases is shown in Figure 1 . Cytoplasmic staining for PKCi was somewhat higher in hyperplasia than in normal tissue. PKCi expression was not significantly different between ductal carcinoma in situ, invasive ductal carcinoma and lymph node metastases; however PKCi expression was significantly higher in all of these when compared with hyperplasia (Po0.05 for each of the three comparisons; see Supplementary Table 1) . Cytoplasmic PKCi expression is therefore increased at an early stage in breast cancer development and is maintained in metastatic disease.
PKCi expression in breast cancer cell lines Levels of PKCi were assessed in four different breast cancer cell lines (MCF7, T47D, MDA-MB-231 and BT549) by western blotting and compared with expression levels in two breast epithelial cell lines, MCF10A and hTert-HMEC (human mammary epithelial cells transduced with telomerase). Expression levels were similar between the two breast epithelial cell lines (Figure 2a) . Levels of PKCi protein were higher in three of the four breast cancer cell lines analyzed. To determine whether these reflected increased activity of PKCi, western blots were also probed with an antibody specific for PKCi phosphorylated at Thr555. Phosphorylation of this site, in the turn motif of the PKCi catalytic domain, is a feature of activation of this and other AGC kinase-family members (Freeley et al., 2011) . Two of the four breast cancer cell lines (MCF7 and T47D) also showed marked increases in the levels of phosphorylated PKCi. Normalizing this to total PKCi levels showed that there was an increase in the proportion of PKCi that is activated in these two cell lines (Figure 2b ).
PIK3CA mutations increase the expression and activation of PKCi
The two cell lines that showed the highest expression and activation of PKCi have been shown previously to have PIK3CA mutations and this was confirmed in our lab (E545K for MCF7 and H1047R for T47D). To directly assess the effects of PIK3CA mutations on PKCi expression and activation, MCF10A cells expressing wild-type and the E545K and H1047R mutants of PIK3CA were made using retroviral transduction, as described previously. Figure 2c shows a western blot analysis of the PKCi expression and activation status in these cells grown in the absence of growth factors. Both PIK3CA mutants, but not wild-type PIK3CA, increased the levels of PKCi reproducibly (Figure 2d ). This effect was more marked with the H1047R mutant, consistent with the very high expression seen in T47D cells that also have this specific mutation. Both mutant forms of PIK3CA, but not wild-type, also increased the levels of phosphorylated PKCi. Constitutively active PIK3CA mutants therefore increase both the expression and activation of PKCi.
PKCi promotes breast cancer cell proliferation by repressing senescence Transient transfection of RNA duplexes targeting PKCi effectively reduced its levels in both MCF7 cells and T47D cells (Figure 3a) . Levels of PKCi remained low for up to 6 days after transfection (the longest time point tested). Depletion of PKCi with two different RNA duplexes decreased proliferation in MCF7 and T47D cells (Figure 3b ). This occurred in the absence of any detectable increase in cell death, as assessed by flow cytometry. Cultures of MCF7 and T47D cells depleted of PKCi also showed a decrease in the percentage of cells incorporating 5-bromodeoxyuridine (BrdU), consistent with decreased cell division causing the decrease in viable cell numbers observed (Figure 3c DNA damage (either telomeric in the case of replicative senescence or non-telomeric in the case of premature senescence) is a common, although not universally observed (Denoyelle et al., 2006; Lin et al., 2010) , feature of senescence and DNA-damage responses have an important role in the initiation and maintenance of the senescent phenotype . To assay whether DNA-damage response pathways were activated upon PKCi depletion in breast cancer cells, the presence of gH2AX foci was assessed by immunofluorescence microscopy. As positive control, cells were treated with adriamycin, which has been shown previously to induce senescence through DNA damage and induced senescence in the cell lines used in this study. As expected with adriamycin treatment, cells showed the presence of numerous nuclear foci staining positive for gH2AX that were still present 5 days after adriamycin treatment. However in MCF7 cells in which senescence was induced by PKCi depletion, the numbers of gH2AX foci were not significantly higher than in control cells (Figure 5a ).
Multiple studies have indicated a key role for the cellcycle-inhibitory protein p21 in senescence induction. To assess the role of p21 in the senescence induction after PKCi depletion, small interfering RNAs targeting p21 and PKCi were used either separately or in combination to simultaneously deplete cells of both proteins (Figure 5b ). Depletion of p21 levels in MCF7 cells prevented senescence induction with PKCi depletion, demonstrating an essential role for p21 in this process ( Figure 5c ).
Previous data have linked impaired mitosis to senescence activation (Baker et al., 2004; Lin et al., 2010) , and our recent data have indicated a role for PKCi in mitosis (Baldwin et al., 2010) . As an alternate means to impairing mitosis, the effects of aurora kinase inhibition on senescence were assessed, both in the absence and presence of PKCi depletion. The aurora kinases are known to have a central role in the control of mitosis (Barr and Gergely, 2007) . The pan-aurora kinase inhibitor VX-680 was used for these experiments (Harrington et al., 2004) . VX-680 on its own caused an increase in the number of senescent MCF7 cells and also enhanced the effects of PKCi depletion on senescence induction (Figure 6a ). VX-680, either alone or in combination with PKCi depletion, did not increase the numbers of gH2AX foci beyond those seen in control cells, suggesting that the two treatments promote senescence by similar mechanisms (Figure 6b ). Consistent with results reported for the aurora kinase-A-selective inhibitors MLN8237 and MLN8054 (Gorgun et al., 2010; Huck et al., 2010) , VX-680 also increased the levels of p21 in MCF7 cells prior to the onset of the senescence phenotype (Figures 6c and d ). PKCi depletion does not induce senescence in normal breast epithelial cells In hTert-HMEC cells, depletion of PKCi had no effect on proliferation (Figures 7a and b) . These cells had undetectable basal levels of SA-b-gal positivity and no increase in positivity was seen upon PKCi depletion (Figure 7c ). Similarly, PKCi depletion did not have a significant effect on SA-b-gal positivity in MCF10A normal breast epithelial cells, even though these cells had relatively high basal levels of SA-b-gal positivity (similar to levels seen in T47D cells) (Figure 7c ).
PKCi represses senescence in glioblastoma
PKCi depletion also increased the proportion of SA-bgal-positive cells in three different glioblastoma cell lines (U87MG, A172 and DBTRG) (Figures 8a and b) . In these cells, PKCi is activated by loss of PTEN rather than by PIK3CA mutation (Baldwin et al., 2008) .
Glioblastoma cells that were SA-b-gal-positive also showed an enlarged, flattened morphology, confirming they were senescent ( Figure 8c ). As with MCF7 breast cancer cells, senescence occurred in the absence of a detectable DNA-damage response (Figures 9a and b) and was dependent on the presence of p21 (Figures 9c  and d ). VX-680 also caused an increase in the number of senescent U87MG cells (Figure 10a ), although only with longer (72 h) exposures to the drug. With shorter (24 h) exposures, VX-680 treatment did not produce a statistically significant increase in senescent U87MG cells, but did sensitize them to senescence induction upon PKCi depletion (Figure 10b ). This also occurred without any evidence for activation of the DNA-damage response (Figure 10c ). VX-680 treatment also caused an increase in p21 levels in U87MG cells, although as with senescence induction this was only evident with longer exposures to VX-680 ( Figure 10d ). 
Discussion
Overexpression of PKCi in breast cancer has been reported previously by Kojima et al. (2008) . Our findings are consistent with the results of this previous study, except that we observed PKCi overexpression in ductal carcinoma in situ. We also found that PKCi is overexpressed in lymph node metastases (76%), which were not assessed in the study by Kojima et al. The causes of increased PKCi expression in breast cancer have not been studied previously in detail. To address this, we evaluated PKCi expression in breast cancer cell lines. A subset of breast cancer cell lines also overexpressed PKCi and showed increased activation of this kinase. Both overexpression and activation could be induced by mutant, constitutively active PIK3CA. PIK3CA mutations are present in 25-30% of breast cancers (Karakas et al., 2006) . As we and others have observed overexpression of PKCi in 70-80% of breast cancers, additional factors are probably also able to drive this overexpression. Likely candidates are PTEN loss and Her2 activation, both of which also constitutively activate the PI-3-kinase pathway. This suggests that elevated PKCi levels might be a general marker of enhanced PI-3-kinase signaling in breast cancer cells. PKCi levels could therefore be a useful biomarker for identifying patients that benefit from therapeutics targeting this pathway, although clearly this requires further study. Increases in PKCi mRNA levels were not sufficient to explain the increases in PKCi protein levels (Supplementary Figure 1A) . A likely explanation for the increase in PKCi protein levels is that phosphorylation stabilizes the enzyme, as has been shown for the other members of the PKC family (Bornancin and Parker, 1996; Freeley et al., 2011) .
The finding that PIK3CA mutations activate PKCi emphasizes the point made previously in the literature that, although Akt is a major downstream mediator in the PI-3-kinase pathway, multiple other downstream signaling events are also important (Vanhaesebroeck and . Recent data show that activation of Akt downstream from mutant PIK3CA is not observed robustly in all cell types, further emphasizing the importance of additional downstream signaling events (Vasudevan et al., 2009) . Although both PKCi and PKB/Akt are activated by PI-3-kinase signaling, there are potential differences in the details of their activation mechanism. Notably, the atypical PKCs, have an acidic amino acid in place of a serine in their hydrophobic motif region (Vanhaesebroeck and Alessi, 2000) . In most other AGC kinases, including PKB/Akt, serine phosphorylation at this site by the mTORC2 complex primes the kinase for PI-3-kinase activation (Pearce et al., 2010) . The presence of an acidic residue allows the atypical PKCs to constitutively associate with PDK1 (Balendran et al., 2000) . In addition, this acidic residue should render the atypical PKCs resistant to the protein phosphatase PHLPP, which inactivates Akt by dephosphorylating its hydrophobic motif (Gao et al., 2005) .
The consequences of increased PKCi in breast cancer have also not been studied previously in detail. We used RNA interference to deplete breast cancer cells of this enzyme. In agreement with our previous results in glioblastoma cells, and the results of others in breast cancer cells (Nolan et al., 2008) , we found that PKCi depletion reduced the growth rate of breast cancer cells. As this was due to decreased proliferation rather than increased cell death, we investigated whether PKCi affected senescence in these cells. We found that PKCi depletion lead to increased numbers of senescent cells. This was initially assessed by using assays for SA-b-gal. The senescent phenotype of these cells was confirmed by their flattened morphology and their lack of BrdU incorporation. PKCi depletion promoted senescence in MCF7 and T47D breast cancer cells, both of which have PIK3CA mutations, but did not promote senescence in MDA-MB-231 cells, which lack this mutation (Supplementary Figure 1B ). We extended these findings, showing that PKCi depletion also promotes senescence in three different glioblastoma cells lines, in which the PI-3-kinase pathway is activated by PTEN loss rather than by PIK3CA mutation (Ishii et al., 1999) .
PKCi depletion induced senescence in T47D cells, which have a mutant p53 (O'Connor et al., 1997), and in MCF7 and U87MG cells, which are mutated at the INK4a/ARF locus (Herman et al., 1995; Ishii et al., 1999) . Thus there is no absolute requirement for p53, p16 or ARF in the senescent pathway involved (although it is formally possible that they could enhance senescence through this pathway). Activation of a DNA-damage response is a feature of replicative senescence and is also a feature of some forms of oncogene-induced senescence (Di Micco et al., 2006) . We did not see any evidence for activation of the DNA-damage response with PKCi depletion in either breast cancer or glioblastoma cells. Other groups have also described senescence that occurs in the absence of detectable DNA-damage response pathway activation (Denoyelle et al., 2006; Lin et al., 2010) . The lack of a requirement for p53 and p16, along with the absence of activation of a DNA-damage response, suggests a novel mechanism for senescence induction upon PKCi depletion.
We have shown previously that depletion of PKCi results in defects in mitosis (Baldwin et al., 2010) . A recent paper has described senescence activation in the absence of DNA damage in mice that have cell-cycle defects owing to loss of Skp2 expression (Lin et al., 2010) . Mice that are hypomorphic for the spindle checkpoint kinase Bub1 also show enhanced senescence (Baker et al., 2004) . It therefore seems possible that there is a second mechanism for senescence induction that is triggered by mitosis defects and which is independent of activation of the DNA-damage response pathway. Consistent with this hypothesis, we found that impairment of mitosis with the aurora kinase inhibitor VX-680 also promotes senescence in both breast and brain cancer cells. Shorter VX-680 exposures sensitized glioblastoma cells to the effects of PKCi depletion on senescence, suggesting that PKCi depletion and VX-680 treatment induce senescence by related mechanisms. Also consistent with a related mechanism, both treatments induced senescence in the absence of a detectable DNA-damage response.
Senescence induction with PKCi depletion was markedly dependent on the presence of the cell-cycleregulatory protein p21. Many studies have demonstrated a role for p21 in promoting senescence, although often this has been as a consequence of its activation through the DNA-damage response pathway and p53 (Schmitt, 2007) . p21 has previously been shown to be a direct substrate for the atypical PKCs, which appear to inactivate p21 by phosphorylation at a serine residue in the C-terminus (Scott et al., 2002) . This suggests a model for senescence induction by PKCi depletion in which decreased PKCi phosphorylation leads to p21 activation directly, without the need for p21 activation through the DNA-damage response pathway and p53. Aurora kinase inhibition with VX-680 increased the levels of p21, presumably by preventing its degradation at the initiation of mitosis. VX-680 treatment and PKCi depletion may therefore cooperate to promote cancer cell senescence by simultaneously increasing p21 levels and p21 activation, respectively, in cancer cells attempting to initiate mitosis.
We did not observe any effects of PKCi depletion on senescence in two normal breast cancer cell lines, showing that depletion of PKCi induces cancer cellspecific reactivation of oncogene-induced senescence. Given the evidence that PI-3-kinase pathway activation may either promote or repress senescence, two possible models can be proposed. In the first model, PKCi could be mediating downstream anti-senescent activity of the PI-3-kinase pathway, which prevents oncogene-induced senescence by a second oncogenic pathway. This model is suggested by data from mouse models of melanoma, where PI-3-kinase pathway signaling appears to prevent oncogene-induced senescence driven by mutant BRAF (Dankort et al., 2009) . In an alternate model, PKCi might attenuate oncogene-induced senescence driven by the PI-3-kinase pathway itself. This model is suggested by the pro-senescent effects of PTEN loss in mouse models of prostate cancer (Chen et al., 2005) . We only observed senescence induction after PKCi depletion in cells with mutations in PIK3CA or with loss of PTEN. If the second model is correct, it provides a straightforward explanation as to why this phenomenon is apparently restricted to cells with these mutations. In summary, we have identified a novel role for PKCi in repressing oncogene-induced senescence. PKCi fulfills this role in cells in which the PI-3-kinase pathway is activated by mutations in either PIK3CA or in PTEN. Inhibition of PKCi activated senescence in cancer cells by a mechanism that did not require activation of a DNA-damage response, but may instead be triggered by defects in the initiation of mitosis.
Materials and methods
Antibodies and inhibitors
PKCi mouse monoclonal and phospho-threonine-555 PKCi rabbit polyclonal antibodies were from BD Transduction Laboratories (Mississauga, ON, Canada) and Invitrogen (Carlsbad, CA, USA), respectively. The Akt goat polyclonal and pAkt (Ser473) rabbit polyclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Cell Signaling Technology (Danvers, MA, USA), respectively. The GAPDH (glyceraldehyde-3-phosphate dehydrogenase) antibody was from Abcam (Cambridge, MA, USA). Antibodies to gH2AX (phospho-histone H2A.X (Ser139)) were from Millipore (Billerica, MA, USA). The rabbit monoclonal antibody to p21 was from Cell Signaling Technology (Danvers, MA, USA). The mouse monoclonal actin antibody was purchased from Sigma-Aldrich Canada (Oakville, ON, Canada). All secondary antibodies were purchased from Jackson Immunoresearch Laboratories (West Grove, PA, USA). VX-680 was from Selleck Chemicals (Houston, TX, USA). Adriamycin was from the Ottawa Hospital Cancer Centre Pharmacy.
Cell culture
The MCF-10A, HTERT-HMEC, MDA-MB-231, MCF7, BT549, T47D, A172 and DBTRG cell lines were all purchased from ATCC. The human U87MG glioblastoma cell line was obtained from Dr W Cavenee (Ludwig Institute for Cancer Research, La Jolla, CA, USA). All cell lines were passaged for less than 6 months continuously and were routinely checked for mycoplasma contamination.
Expression constructs and retroviral transduction
The JP1520 vector was purchased from Harvard Institute of Proteomics (Boston, MA, USA). The JP1520/PIK3CA, JP1520/E545K and JP1520/H1047R constructs were created by Isakoff et al. (2005) , and purchased from Addgene (Cambridge, MA, USA) (Addgene plasmids 14570, 14571, 14572). Replication-incompetent retroviruses were constructed as described previously (Lorimer and Lavictoire, 2000) and used to transduce MCF10A cells. All experiments were performed using transduced populations of cells that were selected with 1 mg/ml puromycin.
Immunohistochemistry
Tissue microarray slides were purchased from US Biomax Company (Rockville, MD, USA). For PKCi staining, antigen retrieval was performed using sodium citrate (pH 6) and microwave treatment. Primary mouse monoclonal PKCi antibody was used at a concentration of 10 mg/ml and was detected with the Envision Polymer Detection System (Dako, Mississauga, ON, Canada). A scoring system from 0 to 3 þ based on the intensity of cytoplasmic staining of tumor cells was used, with 3 þ being the strongest staining. Scoring was performed independently by a general pathologist (MD) and a surgical oncologist (SA).
Western blot analysis
Western blots were performed as described previously (Baldwin et al., 2006) . Western blots were quantified by densitometry using the GeneGnome chemiluminescent system and the Syngene software, or the Alpha Innotech Fluorchem system and the Alphaview software.
RNA interference RNA duplexes with the following sense strand sequences were used to target PKCi: duplex-A, 5
0 -GTGCATCAACTGCAAA CTC-3 0 (Baldwin et al., 2006) ; duplex-C, 5 0 -CTTCCTGAAGA ACATGCCA-3 0 (Xu and Deng, 2006) ; duplex-E, 5 0 -GCCTG GATACAATTAACCATT-3 0 (Scotti et al., 2010) . Sense strand sequences of RNA duplexes targeting p21 were as follows: duplex-B, 5 0 -GCCTTAGTCTCAGTTTGTGTG; duplex-C, 5 0 -GATGGAACTTCGACTTTGT. All duplexes were purchased from Dharmacon (Lafayette, CO, USA). SiGENOME non-targeting small interfering RNA #2 and #3 from Dharmacon were used as controls. RNA transfections were performed as described previously (Baldwin et al., 2006) .
Proliferation assays
RNA transfections were performed 24 h after plating cells. Viable cells were counted at the indicated time points after transfection using a Vi-Cell XR cell counter (Beckman Coulter, Mississauga, ON, Canada).
SA-b-gal staining
Cells were plated on gelatin-coated coverslips in each well of a six-well dish. Twenty-four hours later, transfection of RNA duplexes was performed as described above. Medium was refreshed every 48 h. At the indicated number of days after transfection, cells were fixed in 4% paraformaldehyde and assayed for SA-b-gal activity as described (Debacq-Chainiaux et al., 2009). Slides were analyzed using a Zeiss Axioskop 2 microscope. Total and SA-b-gal-positive cells were counted in a minimum of three separate fields for each condition.
Morphology
Slides were analyzed using a Nikon Eclipse TE 2000-U microscope using Â 20 magnification. Representative pictures were taken using a Coolpix MDC lens (Nikon Canada inc., Mississauga, ON, Canada) and a Nikon 5400 digital camera.
BrdU incorporation MCF7 and T47D cells were plated on gelatin-coated coverslips and transfected with RNA duplexes the following day. Medium was refreshed every 48 h. Six days after transfection, BrdU (Sigma-Aldrich, Oakville, ON, Canada) was added to fresh medium on cells at a concentration of 10 mM. After 2 h, cells were fixed with 70% ethanol. Incorporated BrdU was detected using a BrdU mouse monoclonal antibody from Cell Signaling (Danvers, MA, USA) and an Alexa-Fluor-555 goat anti-mouse antibody as the secondary antibody. Total and BrdU-positive nuclei were counted under a Zeiss Axioplan 2 microscope. A minimum of three fields and 250 nuclei were counted for each condition.
Immunofluorescent staining for gH2AX Cells on gelatin-coated coverslips were fixed for 30 min with 4% paraformaldehyde and permeabilized for 10 min using 0.2% Triton X-100. After blocking in 5% normal goat serum in phosphate-buffered saline, cells were incubated with an antigH2AX antibody for 1 h at a 1:800 dilution in 5% normal goat serum. This was followed by a 1-h incubation with the AlexaFluor-555 goat anti-mouse secondary antibody at 2 mg/ml in 5% normal goat serum. A minimum of 100 cells over a minimum of four fields were counted, and nuclei with five or more foci were considered positive, as proposed by Lawless et al. (2010) .
Statistical analysis
Unless otherwise indicated, all values are represented as the average of three independent experiments, with error bars indicating the standard error of the mean. Statistical significance was determined by a two-tailed t-test. Values were considered significant when Po0.05.
